Genetic susceptibility and clinical features of CYP2D6 associated with systemic lupus erythematosus in a Chinese population.
Luo X, Du J, Zhao J, Fan M, Luo X, Zhao P, Zheng P, Mo L, Li Y.

Exploring CYP2D6 polymorphisms and angiotensin receptor blocker response in the Bai hypertensive population.
Yang C, Zhang G, Shu C, Lv L, Liu Z, Tian Y, Tan Q, Wang Z, Hu S, Yang L, Sun N., Free PMC Article

CYP2D6, CYP2E1 Gene Polymorphisms and Gastrointestinal Cancer Risk in Rural Maharashtra: A Hospital Based Case-Control Study.
Datkhile KD, More AL, Patil MN, Gudur RA, Gudur AK.

Clinical and Adverse Outcomes Associated With Concomitant Use of CYP2D6-Metabolized Opioids With Antidepressants in Older Nursing Home Residents : A Target Trial Emulation Study.
Wei YJ, Winterstein AG, Schmidt S, Fillingim RB, Daniels MJ, DeKosky ST, Schmidt S.

The potential Role of CYP2D6*10(c.100 C>T) Gene Polymorphism in Kidney Injury of Patients with Hypertension Complicated with Non-Elevated Cystatin C.
Jiang Y, Wang K, Mei X, Zhou Y.

Molecular Mechanisms Underlying Single Nucleotide Polymorphism-Induced Reactivity Decrease in CYP2D6.
Becker D, Bharatam PV, Gohlke H.

Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis.
Li D, Pain O, Fabbri C, Wong WLE, Lo CWH, Ripke S, Cattaneo A, Souery D, Dernovsek MZ, Henigsberg N, Hauser J, Lewis G, Mors O, Perroud N, Rietschel M, Uher R, Maier W, Baune BT, Biernacka JM, Bondolfi G, Domschke K, Kato M, Liu YL, Serretti A, Tsai SJ, Weinshilboum R, GSRD Consortium, the Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, McIntosh AM, Lewis CM., Free PMC Article

Prevalence of CYP2D6 structural variation in large retrospective study.
Frear S, Sherman A, Rule D, Marcath LA.

Effects of CYP2D6 *10 and *41 Variants in Healthy Chinese Men on the Pharmacokinetics of Dapoxetine.
Wang Z, Gao Y, Ji X, Wu T, Pu L, Qiu W.

Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D6*17 and CYP2D6*29, When Compared with Normal Metabolizers.
Marasanapalle VP, Masimirembwa C, Sivasubramanian R, Sayyed S, Weinzierl-Hinum A, Mehta D, Kapungu NN, Kanji C, Thelingwani R, Zack J.

Identification of the effects of pathogenic genetic variations of human CYP2C9 and CYP2D6: an in silico approach.
Avsar O.

Functional maturation of cytochromes P450 3A4 and 2D6 relies on GAPDH- and Hsp90-Dependent heme allocation.
Islam S, Jayaram DT, Biswas P, Stuehr DJ., Free PMC Article

A consideration of CYP2D6 genetic variations in the Ghanaian population as a potential 'culprit' for the tramadol 'abuse crisis'.
Thomford NE, Abraham SA, Nyarko SB, Biney RP., Free PMC Article

CYP2D6 Genotyping and Inhibition as Predictors of Adverse Drug Reactions in Depressive Disorders.
Holck A, Asp M, Green H, Westrin Å, Reis M.

Novel Independent Trans- and Cis-Genetic Variants Associated with CYP2D6 Expression and Activity in Human Livers.
Smith D, He B, Shi J, Zhu HJ, Wang X.,

Nrf2 Regulates the Expression of CYP2D6 by Inhibiting the Activity of Krüppel-Like Factor 9 (KLF9).
Siswanto FM, Handayani MDN, Firmasyah RD, Oguro A, Imaoka S.

Associations between Selected ADRB1 and CYP2D6 Gene Polymorphisms in Children with Ventricular and Supraventricular Arrhythmias.
Moric-Janiszewska E, Smolik S, Szydłowski L, Kapral M., Free PMC Article

Effects of CYP2D6 allelic variants on therapy with tamsulosin in patients with benign prostatic hyperplasia.
Abdullaev SP, Shatokhin MN, Tuchkova SN, Abdullaev SP, Teodorovich OV, Loran OB, Sychev DA.

Utility of CYP2D6 copy number variants as prognostic biomarker in localized anal squamous cell carcinoma.
Trilla-Fuertes L, Gámez-Pozo A, Nogué M, Busquier I, Arias F, López-Campos F, Fernández-Montes A, Ruiz A, Velázquez C, Martín-Bravo C, Pérez-Ruiz E, Asensio E, Hernández-Yagüe X, Rodrigues A, Ghanem I, López-Vacas R, Hafez A, Arias P, Dapía I, Solís M, Dittmann A, Ramos R, Llorens C, Maurel J, Campos-Barros Á, Fresno Vara JÁ, Feliu J.

Decreased Analgesic Effect of Tramadol in Japanese Patients with CYP2D6 Intermediate Metabolizers after Orthopedic Surgery.
Kamiya T, Hira D, Nakajima R, Shinoda K, Motomochi A, Morikochi A, Ikeda Y, Isono T, Akabane M, Ueshima S, Kakumoto M, Imai S, Morita SY, Terada T.

The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders.
Kibitov AA, Kiryanova EM, Salnikova LI, Bure IV, Shmukler AB, Kibitov AO.

CYP2D6 genetic polymorphisms in Saudi systemic lupus erythematosus patients: A cross-sectional study.
Hassen LM, Daghestani MH, Omair MA, Althomali AK, Almukaynizi FB, Almaghlouth IA., Free PMC Article

Epigenetic changes in the CYP2D6 gene are related to severity of suicide attempt: A cross-sectional study of suicide attempters.
Boström AED, Jamshidi E, Manu DM, Kular L, Schiöth HB, Åsberg M, Jokinen J.

Cross-Ancestry Genome-Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations.
Khor CC, Winter S, Sutiman N, Mürdter TE, Chen S, Lim JSL, Li Z, Li J, Sim KS, Ganchev B, Eccles D, Eccles B, Tapper W, Zgheib NK, Tfayli A, Ng RCH, Yap YS, Lim E, Wong M, Wong NS, Ang PCS, Dent R, Tremmel R, Klein K, Schaeffeler E, Zhou Y, Lauschke VM, Eichelbaum M, Schwab M, Brauch HB, Chowbay B, Schroth W.

CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients.
Dalle Fratte C, Gagno S, Roncato R, Polesel J, Zanchetta M, Buzzo M, Posocco B, De Mattia E, Borsatti R, Puglisi F, Foltran L, Guardascione M, Buonadonna A, Cecchin E, Toffoli G.